|
Dallas–Fort Worth, TX Press Releases
|
(Dallas.CityRegions.Com, October 25, 2014 ) Dallas, TX -- Researcher has released its new PharmaPoint Drug Evaluation report, “Neratinib HER2-Positive Breast Cancer Forecast and Market Analysis to 2023″. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line metastatic.
Puma Biotechnology’s neratinib is an orally-administered TKI that binds irreversibly, targeting HER1, HER2, and HER4. Neratinib inhibits HER2 at a different site than the currently marketed HER2-targeted therapies, which Puma believes will make it effective in patients who have developed resistance to these other treatments.
Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=232643 .
Scope
• Overview of HER2-Positive Breast Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Neratinib including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Neratinib for the top eight countries from 2013 to 2023.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.
Reasons to buy
• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for HER2-Positive Breast Cancer
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Neratinib performance
• Obtain sales forecast for Neratinib from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=232643 . (Single User License : US$ 3495 And Corporate User License : US$ 10485)
Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Basic Breast Anatomy 14
3.3 Breast Cancer Staging 15
3.4 Prognosis 16
3.5 Quality of Life 17
3.6 Symptoms 19
4 Disease Management 20
4.1 Treatment Overview 20
4.1.1 Treatment of Early-Stage Breast Cancer (Stage 0 to Stage IB) 20
4.1.2 Treatment of Locally-Advanced and Regional Breast Cancer (Stage IB to IIIA) 21
4.1.3 Treatment of Metastatic HER2-Positive Breast Cancer (Stage IV) 24
5 Competitive Assessment 27
5.1 Overview 27
6 Unmet Need and Opportunity 29
6.1 Overview 29
6.2 Brain Metastases 30
6.2.1 Unmet Need 30
6.2.2 Gap Analysis 30
6.2.3 Opportunity 32
6.3 Resistance to HER2-Targeting Therapies 32
6.3.1 Unmet Need 32
6.3.2 Gap Analysis 33
6.3.3 Opportunity 34
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 1-888-391-5441
sales@rnrmarketresearch.com
Source: EmailWire.Com
|
|
|
|